🟢 NanoViricides is trading 6% up in pre-market; Ebola trial update's role is unconfirmed

NanoViricides is trading at $1.40, up 5.95% in pre-market, with its Ebola trial update as relevant but unconfirmed context.

• On October 13, 2026, NanoViricides said its Phase IIA NV-387 oral-gummy Ebola trial was enrolling and progressing well.
• The release gave no patient count or interim results, and neither it nor available coverage confirms the update caused the pre-market rise.
• Market context was mixed, with no broad index move above 0.5% in the same direction.